Breast Cancer
News
Axillary Dissection Often Unnecessary in Early Breast Cancer
Major Finding: The 5-year disease-free survival rate among breast cancer patients with minimal sentinel node involvement was 88.4% of women who...
News
AVEREL: Avastin Defers Progression in HER2-Positive Metastatic Breast Cancer*
Major Finding: In an assessment conducted by investigators, bevacizumab significantly improved progression-free survival when added to standard...
Conference Coverage
ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer
Major Finding: Immediate treatment with zoledronic acid reduced recurrence and mortality risk by 34% and 31%, respectively, and improved bone...
News
Breast-Mammogram Detector Mismatch Results in Excess Radiation
Major Finding: Screening mammogram patients with correctly matched breast and detector sizes received an average mean glandular dose per breast of...
News
Clodronate Offered Modest Benefit for Breast Cancer Patients
Major Finding: Disease-free survival (DFS) did not differ between women treated with clodronate and those given placebo (hazard ratio, 0.91; P = ....
News
DCIS Assay Predicts Recurrence Risk After Breast Surgery
Major Finding: Twelve percent of patients with a low DCIS risk score experienced a disease recurrence within 10 years of breast-conserving surgery...
News
Dual HER2 Blockade Defers Breast Cancer Progression
Major Finding: Adding pertuzumab to a standard chemotherapy regimen of trastuzumab and docetaxel led to an additional 6 months of progression-free...
Conference Coverage
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
Major Finding: According to updated results median progression-free survival was 7.4 months for combination therapy patients and 3.2 months for...
News
IOM Dissects Environmental Risk Factors for Breast Cancer
News
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
Major Finding: Treatment with zoledronic acid led to a 28% reduction in breast cancer recurrence risk and a 37% reduction in mortality risk over 7...